Form 13-F position report

ACUMEN PHARMACEUTICALS INC

Reported by MORGAN STANLEY

ABOS CUSIP 00509G209 Manager CIK 0000895421

Reported 15,324 shares, down 36,184 (70.2%) from the prior quarter.

Reported value -64.8%; share count -70.2% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q2 2023
Shares 15,324 Quarter-end amount reported
Reported value $73,710 Fair value at quarter end
Consecutive quarters held 8 Through Q2 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 138000
2022-03-31 53000
2022-06-30 113000
2022-09-30 189000
2022-12-31 138693
2023-03-31 209123
2023-06-30 73710
2023-09-30 92293
2023-12-31 88804
2024-03-31 197284
2024-06-30 212498
2024-09-30 593215
2024-12-31 457892
2025-03-31 167900
2025-06-30 178348
2025-09-30 255476
2025-12-31 352169
2026-03-31 341219
2026-06-30 365157
2026-09-30 198081

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for ACUMEN PHARMACEUTICALS INC held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 89,226 -47,537 (-34.8%) < 0.01% $198,081 2026-11-13
Q2 2026 Reduced 136,763 -7,821 (-5.4%) < 0.01% $365,157 2026-08-13
Q1 2026 Reduced 144,584 -22,321 (-13.4%) < 0.01% $341,219 2026-05-15
Q4 2025 Added 166,905 +17,504 (11.7%) < 0.01% $352,169 2026-02-13
Q3 2025 Reduced 149,401 -4,347 (-2.8%) < 0.01% $255,476 2025-11-14
Q2 2025 Added 153,748 +1,112 (0.7%) < 0.01% $178,348 2025-08-15
Q1 2025 Reduced 152,636 -113,580 (-42.7%) < 0.01% $167,900 2025-05-15
Q4 2024 Added 266,216 +27,016 (11.3%) < 0.01% $457,892 2025-02-14
Q3 2024 Added 239,200 +151,391 (172.4%) < 0.01% $593,215 2024-11-14
Q2 2024 Added 87,809 +39,097 (80.3%) < 0.01% $212,498 2024-08-14
Q1 2024 Added 48,712 +25,586 (110.6%) < 0.01% $197,284 2024-05-15
Q4 2023 Added 23,126 +887 (4.0%) < 0.01% $88,804 2024-02-13
Q3 2023 Added 22,239 +6,915 (45.1%) < 0.01% $92,293 2023-11-15
Q2 2023 Reduced 15,324 -36,184 (-70.2%) < 0.01% $73,710 2023-08-14
Q1 2023 Added 51,508 +25,824 (100.5%) < 0.01% $209,123 2023-05-15
Q4 2022 Added 25,684 +6,770 (35.8%) < 0.01% $138,693 2023-02-14
Q3 2022 Reduced 18,914 -5,026 (-21.0%) < 0.01% $189,000 2022-11-14
Q2 2022 Added 23,940 +10,253 (74.9%) < 0.01% $113,000 2022-08-15
Q1 2022 Reduced 13,687 -6,840 (-33.3%) < 0.01% $53,000 2022-05-13
Q4 2021 Added 20,527 +19,958 (3507.6%) < 0.01% $138,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

71 managers reported ACUMEN PHARMACEUTICALS INC for Q2 2023.

Managers reporting ACUMEN PHARMACEUTICALS INC in Q2 2023.
Manager Activity Shares Change % of reported 13F Reported value Tenure
RA CAPITAL MANAGEMENT L P Unchanged 9,770,773 0 0.89% $46,997,418 8 qtrs
Deep Track Capital LP Reduced 3,916,361 -35,639 0.87% $18,837,696 7 qtrs
Sands Capital Ventures LLC Unchanged 3,417,075 0 4.86% $16,436,131 8 qtrs
Knollwood Investment Advisory LLC Unchanged 1,678,510 0 2.72% $8,073,633 3 qtrs
Laurion Capital Management LP Unchanged 1,206,548 0 0.03% $5,803,496 8 qtrs
MILLENNIUM MANAGEMENT LLC Added 1,146,018 +500,135 < 0.01% $5,512,347 7 qtrs
GREAT POINT PARTNERS LLC Unchanged 1,051,267 0 0.99% $5,056,594 6 qtrs
VANGUARD GROUP INC Added 734,852 +115 < 0.01% $3,534,638 8 qtrs
Ikarian Capital LLC Added 654,945 +400,000 0.5% $3,150,286 4 qtrs
BlackRock Inc Reduced 483,324 -188,307 < 0.01% $2,324,789 8 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2023
Filed
August 14, 2023
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
15,145
Shared
0
None
179

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.